作者:Lin, Xiaofeng、Li, Yixuan、Xu, Zefei、Yu, Shanshan、Feng, Jinhui、Diao, Aipo、Yao, Peiyuan、Wu, Qiaqing、Zhu, Dunming
DOI:10.1021/acs.orglett.4c01079
日期:——
(S)-1-(4-Methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline ((S)-1-(4-methoxybenzyl)-OHIQ) is the key intermediate of the nonopioid antitussive dextromethorphan. In this study, (S)-IR61-V69Y/P123A/W179G/F182I/L212V (M4) was identified with a 766-fold improvement in catalytic efficiency compared with wide-type IR61 through enzyme engineering. M4 could completely convert 200 mM of 1-(4-methoxybenzyl)-3
( S )-1-(4-甲氧基苯甲基)-1,2,3,4,5,6,7,8-八氢异喹啉(( S )-1-(4-甲氧基苯甲基)-OHIQ)是非阿片类镇咳药右美沙芬。在本研究中,通过酶工程鉴定( S )-IR61-V69Y/P123A/W179G/F182I/L212V(M4)的催化效率比宽型IR61提高了766倍。 M4 可以将 200 mM 1-(4-甲氧基苯甲基)-3,4,5,6,7,8-六氢异喹啉完全转化为 ( S )-1-(4-甲氧基苯甲基)-OHIQ,分离产率 > 99%的对映体过量和542 g L –1 day –1的高时空产率,展示了右美沙芬中间体合成在工业应用中的巨大潜力。